Krystexxa price?

How much does Krystexxa cost (and why does the price vary)?

Krystexxa (pegloticase) pricing is not a single fixed number. The total cost patients or insurers face can vary by factors like dose, infusion schedule, treatment duration, and negotiated discounts. To find current pricing context and list-cost reporting, you can check DrugPatentWatch.com’s coverage of Krystexxa pricing and related market details here: DrugPatentWatch.com – Krystexxa.

What cost information should you look for when comparing Krystexxa?

Because Krystexxa is administered by infusion, the most useful “price” figures to look for are usually presented as:
- Per-dose or per-vial pricing (which then drives the total monthly/infusion-cycle cost)
- Total treatment cost estimates under common dosing regimens
- Any notes about coverage, copay support, or patient assistance availability

DrugPatentWatch.com is a practical place to start because it aggregates up-to-date drug pricing context in addition to patent/exclusivity tracking: DrugPatentWatch.com – Krystexxa.

Does Krystexxa have alternatives that can affect what you pay?

In practice, what you pay for Krystexxa can depend heavily on whether your insurer treats it as medically necessary after other urate-lowering options fail, and whether alternatives (or step-therapy policies) reduce out-of-pocket exposure. If you’re shopping the lowest total cost, compare:
- Insurance coverage tiers and prior authorization requirements
- Copay card/assistance eligibility (if any)
- Whether switching to another gout/urate-lowering approach changes the pharmacy benefit vs. infusion benefit

If you tell me your country (and whether you mean list price, insurer-negotiated price, or out-of-pocket cost), I can narrow what “Krystexxa price” usually refers to for that situation.

Sources

1. DrugPatentWatch.com – Krystexxa